15,300 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Integrated Quantitative Investments LLC

Integrated Quantitative Investments LLC bought a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 15,300 shares of the biopharmaceutical company's stock, valued at approximately $390,000.

A number of other institutional investors also recently modified their holdings of RPRX. Verition Fund Management LLC boosted its position in Royalty Pharma by 39.7% during the third quarter. Verition Fund Management LLC now owns 27,869 shares of the biopharmaceutical company's stock valued at $788,000 after acquiring an additional 7,919 shares during the last quarter. Investment Management Corp of Ontario boosted its position in shares of Royalty Pharma by 47.5% during the 3rd quarter. Investment Management Corp of Ontario now owns 12,733 shares of the biopharmaceutical company's stock valued at $360,000 after purchasing an additional 4,100 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Royalty Pharma during the third quarter worth approximately $14,898,000. Royal London Asset Management Ltd. increased its holdings in Royalty Pharma by 2.8% in the third quarter. Royal London Asset Management Ltd. now owns 160,184 shares of the biopharmaceutical company's stock worth $4,532,000 after purchasing an additional 4,307 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its stake in Royalty Pharma by 43.0% in the third quarter. Quantinno Capital Management LP now owns 56,435 shares of the biopharmaceutical company's stock valued at $1,597,000 after buying an additional 16,982 shares during the period. 54.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RPRX has been the subject of several recent analyst reports. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of "Buy" and an average price target of $41.60.

Royalty Pharma Stock Down 4.7 %

Shares of NASDAQ RPRX traded down $1.51 during mid-day trading on Thursday, reaching $30.76. 2,583,628 shares of the company's stock traded hands, compared to its average volume of 3,212,879. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The business has a 50-day simple moving average of $32.49 and a 200 day simple moving average of $29.08. The stock has a market cap of $17.73 billion, a P/E ratio of 21.20, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.